Susquehanna Fundamental Investments LLC Takes Position in BioCryst Pharmaceuticals, Inc. $BCRX

Susquehanna Fundamental Investments LLC acquired a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 91,228 shares of the biotechnology company’s stock, valued at approximately $912,000.

A number of other large investors have also recently bought and sold shares of the business. Moore Capital Management LP bought a new position in shares of BioCryst Pharmaceuticals during the second quarter worth about $8,483,000. Northwestern Mutual Wealth Management Co. increased its stake in shares of BioCryst Pharmaceuticals by 40.2% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 10,254 shares of the biotechnology company’s stock valued at $103,000 after acquiring an additional 2,942 shares during the period. Hsbc Holdings PLC raised its holdings in BioCryst Pharmaceuticals by 247.1% during the second quarter. Hsbc Holdings PLC now owns 109,320 shares of the biotechnology company’s stock worth $1,079,000 after purchasing an additional 77,821 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of BioCryst Pharmaceuticals by 197.2% in the second quarter. Wellington Management Group LLP now owns 293,925 shares of the biotechnology company’s stock valued at $2,939,000 after buying an additional 195,042 shares during the period. Finally, Nantahala Capital Management LLC acquired a new stake in BioCryst Pharmaceuticals in the 2nd quarter valued at about $19,011,600. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock opened at $9.92 on Wednesday. The company has a fifty day moving average price of $9.74 and a two-hundred day moving average price of $9.11. BioCryst Pharmaceuticals, Inc. has a one year low of $6.00 and a one year high of $11.22. The stock has a market cap of $2.53 billion, a P/E ratio of -6.61 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.15. The company had revenue of $218.25 million for the quarter, compared to analyst estimates of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. BioCryst Pharmaceuticals’s revenue for the quarter was up 33.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.15 EPS. As a group, equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen lowered shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. Royal Bank Of Canada dropped their price target on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Wedbush decreased their target price on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Citizens Jmp raised their price objective on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a report on Thursday, May 7th. Finally, HC Wainwright restated a “buy” rating and issued a $32.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Eight equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $20.60.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.